The index, which outperformed the Dow Jones and the Nasdaq this month, gained 11 percent and rebounded from its 11 percent loss in December.
With its stock price languishing below $1, NantHealth has 180 days to come into compliance with Nasdaq listing rules.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.
The expected net proceed are now $5.4 million, down from an earlier anticipated $9.1 million. Investors reacted negatively to the news today.
PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.
After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.
CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.
Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.